Compare IPCA Labs with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs CIPLA - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS CIPLA IPCA LABS/
CIPLA
 
P/E (TTM) x 31.8 33.1 96.1% View Chart
P/BV x 6.6 3.4 194.9% View Chart
Dividend Yield % 0.2 0.5 38.6%  

Financials

 IPCA LABS   CIPLA
EQUITY SHARE DATA
    IPCA LABS
Mar-19
CIPLA
Mar-19
IPCA LABS/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,042678 153.7%   
Low Rs590484 122.0%   
Sales per share (Unadj.) Rs298.6198.2 150.7%  
Earnings per share (Unadj.) Rs35.018.5 188.9%  
Cash flow per share (Unadj.) Rs49.435.0 141.3%  
Dividends per share (Unadj.) Rs3.003.00 100.0%  
Dividend yield (eoy) %0.40.5 71.2%  
Book value per share (Unadj.) Rs247.1186.3 132.6%  
Shares outstanding (eoy) m126.35805.70 15.7%   
Bonus/Rights/Conversions ESOSESOP-  
Price / Sales ratio x2.72.9 93.2%   
Avg P/E ratio x23.331.4 74.3%  
P/CF ratio (eoy) x16.516.6 99.4%  
Price / Book Value ratio x3.33.1 105.9%  
Dividend payout %8.616.2 52.9%   
Avg Mkt Cap Rs m103,108468,031 22.0%   
No. of employees `00013.422.6 59.4%   
Total wages/salary Rs m7,87428,565 27.6%   
Avg. sales/employee Rs Th2,807.07,053.1 39.8%   
Avg. wages/employee Rs Th585.81,261.5 46.4%   
Avg. net profit/employee Rs Th329.0659.1 49.9%   
INCOME DATA
Net Sales Rs m37,732159,710 23.6%  
Other income Rs m5774,766 12.1%   
Total revenues Rs m38,309164,475 23.3%   
Gross profit Rs m6,90130,973 22.3%  
Depreciation Rs m1,82413,263 13.8%   
Interest Rs m1891,684 11.2%   
Profit before tax Rs m5,46520,791 26.3%   
Minority Interest Rs m0-172 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,0425,695 18.3%   
Profit after tax Rs m4,42214,924 29.6%  
Gross profit margin %18.319.4 94.3%  
Effective tax rate %19.127.4 69.6%   
Net profit margin %11.79.3 125.4%  
BALANCE SHEET DATA
Current assets Rs m23,778124,266 19.1%   
Current liabilities Rs m10,97537,715 29.1%   
Net working cap to sales %33.954.2 62.6%  
Current ratio x2.23.3 65.8%  
Inventory Days Days10491 114.5%  
Debtors Days Days6695 69.5%  
Net fixed assets Rs m20,368105,190 19.4%   
Share capital Rs m2531,611 15.7%   
"Free" reserves Rs m30,971148,511 20.9%   
Net worth Rs m31,224150,123 20.8%   
Long term debt Rs m1,40938,301 3.7%   
Total assets Rs m45,507239,633 19.0%  
Interest coverage x30.013.3 224.5%   
Debt to equity ratio x00.3 17.7%  
Sales to assets ratio x0.80.7 124.4%   
Return on assets %10.16.9 146.2%  
Return on equity %14.29.9 142.5%  
Return on capital %17.311.8 146.4%  
Exports to sales %45.934.7 132.2%   
Imports to sales %16.60-   
Exports (fob) Rs m17,30855,419 31.2%   
Imports (cif) Rs m6,266NA-   
Fx inflow Rs m17,30857,410 30.1%   
Fx outflow Rs m6,26619,041 32.9%   
Net fx Rs m11,04238,368 28.8%   
CASH FLOW
From Operations Rs m4,92316,911 29.1%  
From Investments Rs m-1,563-16,687 9.4%  
From Financial Activity Rs m-1,832-3,487 52.5%  
Net Cashflow Rs m1,528-3,451 -44.3%  

Share Holding

Indian Promoters % 45.9 16.0 286.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 11.4 12.2 93.4%  
FIIs % 25.3 23.7 106.8%  
ADR/GDR % 0.0 1.1 -  
Free float % 17.4 26.2 66.4%  
Shareholders   36,892 161,166 22.9%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   NATCO PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  TORRENT PHARMA  PANACEA BIOTECH  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 345 Points Lower; Auto and IT Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure in the last hour of trading and ended their session on a negative note.

Related Views on News

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY20); Net Profit Up 31.2% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, CIPLA has posted a net profit of Rs 5 bn (up 31.2% YoY). Sales on the other hand came in at Rs 44 bn (up 9.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jul 8, 2020 03:35 PM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS